Man Group
CBAY

Man Group’s Cymabay Therapeutics CBAY Stock Holding History

Man Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,469
Closed -$188K – 1859
2022
Q4 		$147K Buy
+23,469
New +$89.2K ﹤0.01% 1829
2018
Q4 		– Sell
-44,900
Closed -$497K – 2162
2018
Q3 		$497K Buy
+44,900
New +$558K ﹤0.01% 1841

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Man Group's CBAY Position: Q1 2023 in Review

Man Group sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 23,469 shares — an estimated $188K sold.

Man Group first reported a position in CBAY in Q3 2018 and held it in 2 quarters. The position peaked at $497K in Q3 2018. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • Man Group reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 23,469 Cymabay Therapeutics shares in Q1 2023, an estimated $188K.
  • Man Group first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 2 quarters.
  • Man Group's Cymabay Therapeutics position peaked at $497K in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.